Indian drugmakers likely to be hit as Trump plans pharmaceutical import tariffs

U.S. President Donald Trump plans to impose 25% or higher tariffs on semiconductors and pharmaceutical imports, increasing over a year. This move is likely to impact India's pharmaceutical industry heavily as the U.S. is their largest market, accounting for significant revenue of major Indian drugmakers like Sun Pharmaceutical, Dr Reddy's, and Cipla.